4D Medical announced a breakthrough. Picture Getty
Health & Biotech
4DMedical (ASX:4DX) has announced a significant technological breakthrough and milestone in its product development strategy.
The company said its CT-based ventilation-perfusion product has now progressed to a developmental stage, which will allow the company to release early clinical data.
This clinical data was presented at the annual conference of the American Thoracic Society in Washington DC yesterday.
The CT:VQ technology enables quantitative perfusion data and visualisations to be extracted from non-contrast paired inspiratory-expiratory CT scans.
It achieves this by measuring the regional motion of lung tissue, while also assessing local density changes to quantify regional blood-mass change.
Through this technology, hospitals can avoid the significant capital expenditure involved in mitigating radiation risks of operating a Nuclear Medicine VQ scanner.
4D Medical CEO and founder Dr Andreas Fouras said that in a matter of years, the company’s XV Technology has set the scene for a step-change in respiratory imaging, disrupting methods that in some cases have been in use for over a century.
“Our progress with CT:VQ keeps us on track for submission to the FDA in calendar 2023, and with an average turn-around time from the FDA, we expect to be in the US market around the middle of calendar 2024,” Fouras said.
Cannabis-centric healthcare company, Bod Australia (ASX:BOD) surged 10% this morning after announcing significant updates regarding its Aqua Phase Delivery technology.
Bod says an ethics approval has been received from Bellberry for its pharmacokinetic (PK) study to compare the bioavailability of cannabidiol (CBD) using Aqua Phase technology, compared with CBD in MCT oil.
Following this approval, Bod will be undertaking two PK studies.
The first study is looking at bioavailability in capillary blood, using micro-sampling technology, demonstrating the amount of the drug that can penetrate organs and the extremities, which is critical for managing diseases in the body.
This study has commenced and currently has 10 volunteers involved. The results of this PK study are anticipated by the end of June.
The second PK study is looking at bioavailability in venous blood.
Ethics approval for this Phase I PK Study has been granted by Bellberry, with recruitment commencing immediately for the 12 study participants to be selected. Recruitment activities will include an initial advertising period, followed by screening and selection.
Results from this study are anticipated to be completed by end July.
Meanwhile, a previous study has shown that Aqua Phase CBD solubility ranges from 1.6 millimolar to 2.7mM.
Solubility is one of the important and main considerations studied during the pre-formulation of any drugs’ dosage form. Water soluble drugs are easy for formulation development, but drugs which show poor water solubility will impose a variety of problems for formulation and development.
“We are increasingly confident in the commercial potential of this unique delivery format in numerous global markets,” said Bod CEO, Jo Patterson.
Leading bio-materials company Nanollose (ASX: NC6) has received a $374,063 R&D Tax Incentive Rebate from the Australian government.
This follows a recent breakthrough for its microbial cellulose dewatering technology which can be applied to the company’s Jelli Grow formulation, complementing its core Nullarbor fibre technology.
Funds from the rebate are expected to considerably strengthen the company’s balance sheet, and provide additional financial flexibility to advance a third pilot spin for its Nullarbor fibres in collaboration with Birla Cellulose.
“The funding comes at an important time in the company’s growth trajectory, with strong R&D momentum for both the Nullarbor fibres and its Jelli Grow formulation,” said Nanollose CEO, Dr Wayne Best.
Best says Nanollose has always been very conscious of its cost base and continues to monitor expenditure.
“The company is also fortunate to have a strong partner base, which brings considerable resources and expertise that can be leveraged to ensure capital is deployed strategically at this critical time in our growth trajectory.”
At Stockhead we tell it like it is. While Nanollose is a Stockhead advertiser, it did not sponsor this article.
Health & Biotech
Health & Biotech
Health & Biotech
Mining
Mining
Mining
Get the latest Stockhead news delivered free to your inbox.
